Floatz logo

Olutasidenib

Cohort 3a and 3b: Chondrosarcoma

Forma Therapeutics, Inc.Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Cohort 3a and 3b: Chondrosarcoma cohort.

Asset / SponsorPhaseRating
ag-120
Memorial Sloan Kettering Cancer Center
Phase 2B
Azacitidine
IGM Biosciences, Inc.
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 1/2CCC
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
Adapt-001
EpicentRx, Inc.
Phase 2CCC

View all 24 →

Same molecule, other indications

Olutasidenib is also rated in:

gliomaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →